

2500 Bates Avenue, Suite B | Concord, California 94520 | Phone: (925) 313-6740 | Fax: (925) 313-6465 cchealth.org

Provider Health Advisory April 18, 2024 Pertussis Cases on the Rise in Contra Costa County

SUMMARY

A recent increase in pertussis (whooping cough) cases has been reported to Contra Costa Health (CCH). Pertussis is highly-contagious and transmission occurs via inhalation of aerosolized droplets from the respiratory tract of an infected person. The incubation period is 4-21 days (typically 7-10 days). Persons ≥1 year of age are considered infectious from the onset of cold-like symptoms until after 5 days of treatment or until 21 days after cough onset if no treatment is given. Infants ≤1 year are considered infectious for 6 weeks if no treatment is given.

CURRENT SITUATION

Fifteen lab-confirmed cases of pertussis have been reported in April 2024. The ages range from 6 months to 50 years, with a median age of 16 years as many cases are of high school age. There has been one hospitalization in the <1 year age group and no deaths have been reported.

Actions Requested of Healthcare Professionals:

- 1. **Submit specimens for laboratory confirmation**. The preferred method of laboratory diagnosis of pertussis is polymerase chain reaction (PCR). Culture is less sensitive than PCR and results can take several days. Serologic assays are not recommended.
- 2. **Begin treatment** of patients regardless of age or vaccination status. <u>Early recognition and treatment of pertussis in infants less than 6 months is important to prevent poor outcomes including death. Students with pertussis should not return to school until 5 days of treatment. Consultation regarding additional control measures is available through Contra Costa Public Health at 925-313-6740.</u>
- 3. **Consider post-exposure prophylaxis (PEP) of high-risk close contacts.** High-risk close contact definition and PEP options are on page 2-3. Please contact Public Health if a high-risk contact needs assistance with obtaining PEP.
- 4. **Review immunization records** and stress the importance of up-to-date vaccination. <u>The most important strategy to prevent infection in vulnerable infants is Tdap vaccination of the mother.</u> All pregnant people should receive Tdap vaccine during each pregnancy, any trimester but preferably between 27-36 weeks gestation, regardless of their vaccination history.
- 5. **Report laboratory-confirmed pertussis cases** within one working day of identification and report suspected pertussis clusters immediately to Contra Costa Health by phone 925-313-6740 or fax 925-313-6465.

CURRENT RECOMMENDATIONS:

CLINICAL

- The most severe cases of pertussis occur in young infants. Infants <6 months of age are
 most likely to be hospitalized and infants <3 months of age are most likely to die from
 pertussis infection.
- Pertussis disease has three stages of illness:
 - 1) Catarrhal stage (early symptoms): onset of cold-like symptoms (coryza, sneezing and occasional cough) and fever is typically absent or low-grade.
 - 2) Paroxysmal stage (later symptoms) spasms of severe cough are followed by sudden deep inspirations, resulting in "whooping" sounds; post-tussive vomiting is common in all ages. Illness may be milder in previously vaccinated people. This stage usually lasts 1-6 weeks but may persist up to 10 weeks.

<u>Important Note</u>: Infants (<6 months of age) may present differently:

- May have a shorter catarrhal stage;
- May gag, gasp or stop breathing (apnea);
- May have facial color changes (turn blue, purple or red);
- May not have noticeable cough or "whoop"; and
- Likely to have leukocytosis with an increased absolute lymphocyte count.
- 3) Convalescent stage (recovery): decreasing frequency and severity of coughing, whooping, and vomiting. Classic pertussis is 6-10 weeks in duration but cough may last longer in some people.

TESTING

- Isolation/culture of *B. pertussis* from clinical specimen or positive polymerase chain reaction (PCR) test for *B. pertussis*. Serological assays are not recommended.
- Specimens for PCR should be obtained by aspiration or swabbing of the posterior nasopharynx (Specimen Collection and Diagnostic Testing | CDC).

TREATMENT

- Treat patients using the appropriate antimicrobial agent (see table below)
- Consider post-exposure prophylaxis of close contacts who are at the highest risk of experiencing severe illness or of transmitting pertussis to high-risk people:
 - Infants <1 year of age, particularly, infants <4 months of age who have not yet received any doses of pertussis vaccine (DTaP)
 - Pregnant people in their third trimester
 - Caregivers and household contacts of infants (family members, friends, or babysitters)
 - Anyone who attends or works in a childcare or healthcare setting
- Lower risk close contacts should self-monitor for symptoms for 21 days after last exposure and seek care if symptoms develop.

Recommended Treatment and Postexposure Prophylaxis, by Age Group[‡]

Age group	Azithromycin	Erythromycin	Clarithromycin	Alternate agent: TMP-SMX
Younger than 1 month	10 mg/kg/day as a single dose daily for 5 days ^{6,**}	40 mg/kg/day in 4 divided doses for 14 days	Not recommended	Contraindicated at younger than 2 months
1 through 5 months	10 mg/kg/day as a single dose daily for 5 days§	40 mg/kg/day in 4 divided doses for 14 days	15 mg/kg/day in 2 divided doses for 7 days	2 months or older: TMP, 8 mg/kg/day; SMX, 40 mg/kg/day in 2 doses for 14 days
6 months or older and children	10 mg/kg as a single dose on day 1 (maximum 500 mg), then 5 mg/kg per day as a single dose on days 2 through 5 (maximum 250 mg/day) ^{§,††}	40 mg/kg/day in 4 divided doses for 7-14 days (maximum 1-2 g per day)	15 mg/kg/day in 2 divided doses for 7 days (maximum 1 g/day)	2 months or older: TMP, 8 mg/kg/day; SMX, 40 mg/kg/day in 2 doses for 14 days
Adolescents and adults	500 mg as a single dose on day 1, then 250 mg as a single dose on days 2 through 5 [§] ,††	2g/day in 4 divided for 7-14 days	1g/day in 2 divided doses for 7 days	TMP 320 mg/day; SMX, 1600 mg/day in 2 divided doses for 14 days.

Source: Red Book 2021-2024

[‡] Centers for Disease Control and Prevention. <u>Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC guidelines. MMWR Recomm Rep. 2005;54(RR-14):1–16</u>

[§] Azithromycin should be used with caution in people with prolonged QT interval and certain proarrhythmic conditions.

^{**} Preferred macrolide for this age because of risk of idiopathic hypertrophic pyloric stenosis associated with erythromycin.

^{††} A 3-day course of azithromycin for PEP or treatment has not been validated and is not recommended.